. 2020 Jul 29;19:178. doi: 10.1186/s12944-020-01352-1

Table 4.

The estimated logistic regression coefficients (β’s), adjusted odds ratios and 95% confidence intervals for the risk of lipid profiles according to the alleles of the haplotype^a according to serum LDL cholesterol concentrations after covariate adjustments

	Model 1	Model 2
Total cholesterol^b (mg/dl)	1	0.084, 0.940 (0.893 ~ 0.988)	− 0.234^***, 0.683 (0.629 ~ 0.742)	0.082, 0.928 (0.881 ~ 0.978)	−0.242^***, 0.669 (0.614 ~ 0.730)
LDL^c (mg/dl)	1	0.098, 0.898 (0.853 ~ 0.946)	−0.249^***, 0.675 (0.592 ~ 0.769)	0.089, 0.956 (0.842 ~ 0.975)	−0.237^***, 0.684 (0.598 ~ 0.782)
HDL^d (mg/dl)	1	0.006, 0.969 (0.917 ~ 1.023)	−0.056, 0.908 (0.837 ~ 0.999)	0.031, 0.966 (0.912 ~ 1.023)	−0.110^***, 0.845 (0.769 ~ 0.928)
Triglyceride^e (mg/dl)	1	−0.026, 1.088 (1.028 ~ 1.151)	0.125^***, 1.243 (1.138 ~ 1.358)	−0.048, 1.110 (1.046 ~ 1.177)	0.188^***, 1.387 (1.265 ~ 1.522)
Ratio of LD and HDL^f	1	0.072^**, 0.905 (0.854 ~ 0.959)	−0.244^***, 0.667 (0.604 ~ 0.737)	0.041, 0.916 (0.876 ~ 1.000)	−0.160^***, 0.770 (0.687 ~ 0.864)
Cardiovascular diseases	1	0.050, 1.018 (0.895–1.158)	−0.096, 0.858 (0.686–1.073)	0.076, 0.968 (0.846–1.108)	− 0.184^*, 0.746 (0.592–0.941)
Myocardial infarction	1	0.067, 0.987 (0.783–1.245)	−0.121, 0.922 (0.624–1.363)	0.086, 0.965 (0.825–1.128)	−0.208^*, 0.719 (0.549–0.943)
Stroke	1	0.002, 1.024 (0.882–1.189)	−0.033, 0.831 (0.639–1.082)	0.032, 0.961 (0.756–1.221)	− 0.105, 0.838 (0.559–1.256)

Model 1

Model 2

Major
(n = 1782)

Heterozygote
(n = 1680)

Minor
(n = 301)

Heterozygote
(n = 1680)

Minor
(n = 301)

Total cholesterol^b

(mg/dl)

0.084, 0.940

(0.893 ~ 0.988)

− 0.234^***, 0.683

(0.629 ~ 0.742)

0.082, 0.928

(0.881 ~ 0.978)

−0.242^***, 0.669

(0.614 ~ 0.730)

LDL^c

(mg/dl)

0.098, 0.898

(0.853 ~ 0.946)

−0.249^***, 0.675

(0.592 ~ 0.769)

0.089, 0.956

(0.842 ~ 0.975)

−0.237^***, 0.684

(0.598 ~ 0.782)

HDL^d

(mg/dl)

0.006, 0.969

(0.917 ~ 1.023)

−0.056, 0.908

(0.837 ~ 0.999)

0.031, 0.966

(0.912 ~ 1.023)

−0.110^***, 0.845

(0.769 ~ 0.928)

Triglyceride^e

(mg/dl)

−0.026, 1.088

(1.028 ~ 1.151)

0.125^***, 1.243

(1.138 ~ 1.358)

−0.048, 1.110

(1.046 ~ 1.177)

0.188^***, 1.387

(1.265 ~ 1.522)

Ratio of LD and HDL^f

0.072^**, 0.905

(0.854 ~ 0.959)

−0.244^***, 0.667

(0.604 ~ 0.737)

0.041, 0.916

(0.876 ~ 1.000)

−0.160^***, 0.770

(0.687 ~ 0.864)

Cardiovascular diseases

0.050, 1.018

(0.895–1.158)

−0.096, 0.858

(0.686–1.073)

0.076, 0.968

(0.846–1.108)

− 0.184^*, 0.746

(0.592–0.941)

Myocardial infarction

0.067, 0.987

(0.783–1.245)

−0.121, 0.922

(0.624–1.363)

0.086, 0.965

(0.825–1.128)

−0.208^*, 0.719

(0.549–0.943)

Stroke

0.002, 1.024

(0.882–1.189)

−0.033, 0.831

(0.639–1.082)

0.032, 0.961

(0.756–1.221)

− 0.105, 0.838

(0.559–1.256)

Values represent odds ratios and 95% confidence intervals

^aHaplotypes of APOE, PVRL2, TOMM40, EXOC3L2, and CD3EAP in the 19q13 loci were generated by PLINK and it was divided into 3 categories (Major, Heterozygote and Minor haplotype groups) by the alleles (0, 1–2, and 3–4). The Major haplotype was the reference for both model 1 and model 2

The cutoff points for dividing the values of each parameter into 2 groups were as follows: the control group included < 200 mg/dL for serum total cholesterol concentrations^b, < 160 mg/dL for serum LDL concentrations (LDL)^c, ≥40 mg/dL for men and ≥ 50 mg/dL for women in serum HDL concentrations (HDL)^d, < 150 mg/dL for serum triglyceride concentrations^e and 2.85 for the ratio of serum LDL concentrations to serum HDL concentrations^f

Model 1: adjusted for age, gender, residence area, body mass index, and energy intake

Model 2: adjusted for the parameter in model 1 plus smoking, coffee, alcohol, physical activity, percent of fat and carbohydrate intakes, menopause, and serum total cholesterol concentrations

^* Significantly changed the risk of hyper-LDL-cholesterolemia by haplotype at P < 0.05, ^** at P < 0.01, and ^*** at P < 0.0001